Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer

@article{Hassanein2015PreclinicalEO,
  title={Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer},
  author={Mohamed Hassanein and Matthew R. Hight and Jason R. Buck and Mohammed Noor Tantawy and Michael L. Nickels and Megan D. Hoeksema and Bradford K. Harris and Kelli Boyd and Pierre P. Massion and H Charles Manning},
  journal={Molecular Imaging and Biology},
  year={2015},
  volume={18},
  pages={18-23}
}
Alanine-serine-cysteine transporter 2 (ASCT2) expression has been demonstrated as a promising lung cancer biomarker. (2S,4R)-4-[18F]Fluoroglutamine (4-[18F]fluoro-Gln) positron emission tomography (PET) was evaluated in preclinical models of non-small cell lung cancer as a quantitative, non-invasive measure of ASCT2 expression. In vivo microPET studies of 4-[18F]fluoro-Gln uptake were undertaken in human cell line xenograft tumor-bearing mice of varying ASCT2 levels, followed by a genetically… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Similar Papers

Loading similar papers…